Axon Enterprise, Inc. (NASDAQ:AXON) Holdings Raised by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH boosted its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 219.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 2,481 shares of the biotechnology company's stock after purchasing an additional 1,705 shares during the quarter. Siemens Fonds Invest GmbH's holdings in Axon Enterprise were worth $1,475,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Axon Enterprise by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock valued at $5,019,886,000 after acquiring an additional 275,959 shares during the period. Geode Capital Management LLC lifted its stake in Axon Enterprise by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock valued at $1,095,542,000 after acquiring an additional 65,097 shares during the period. Capital World Investors lifted its stake in Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after acquiring an additional 841,772 shares during the period. Alliancebernstein L.P. lifted its stake in Axon Enterprise by 273.8% during the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after acquiring an additional 812,337 shares during the period. Finally, Norges Bank bought a new position in Axon Enterprise during the 4th quarter valued at about $482,081,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AXON has been the topic of several recent research reports. Barclays increased their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Needham & Company LLC increased their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. The Goldman Sachs Group increased their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Finally, Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $652.73.

Axon Enterprise Trading Up 1.8%

Shares of NASDAQ:AXON traded up $13.34 during midday trading on Friday, reaching $743.63. 1,121,061 shares of the company's stock were exchanged, compared to its average volume of 732,673. The firm's 50 day simple moving average is $620.57 and its two-hundred day simple moving average is $610.60. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock has a market cap of $57.89 billion, a price-to-earnings ratio of 192.15, a P/E/G ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $755.05.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business's quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.15 EPS. As a group, sell-side analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Insider Activity

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now directly owns 3,063,982 shares of the company's stock, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the firm's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $738.84, for a total value of $960,492.00. Following the completion of the sale, the director now directly owns 4,829 shares in the company, valued at approximately $3,567,858.36. The trade was a 21.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,969 shares of company stock valued at $23,127,314. Company insiders own 5.70% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.